ResolvedStocks

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

First Detected: Apr 16, 2026, 4:17 AM

Last Update: 5 months ago

5 articles·4 stories

Event Summary

On April 16, the US FDA granted Orphan Drug Designation to eftilagimod alfa for the treatment of Soft Tissue Sarcoma (STS). This drug targets a rare cancer with significant unmet medical needs.

Timeline

Cellectar Biosciences Enrolls First Patient in Phase 1b Trial for CLR 125 Breast Cancer Treatment

Apr 16, 2026, 9:17 AMImpact: 5

FDA Grants Fast Track Designation to Climb Bio’s Treatment for Rare Kidney Disease

Apr 16, 2026, 4:30 AMImpact: 6

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

Apr 16, 2026, 4:17 AMImpact: 7

Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

Event Summary

Timeline

Price Impact